![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » INTERMUNE TO SELL RIGHTS TO INFERGEN
INTERMUNE TO SELL RIGHTS TO INFERGEN
November 29, 2005
Drug maker InterMune Inc. is selling its the U.S. and Canadian rights to its Infergen hepatitis C drug to Valeant Pharmaceuticals International for at least $113.5 million, the companies said Monday. InterMune said the divestment is part of a broad cost-cutting plan that will also include cutting 160 full-time jobs and decreasing its spending on certain disease awareness programs. Brisbane, Calif.-based InterMune said the changes will reduce operating expenses by about $50 million a year.
Forbes (http://www.forbes.com/business/feeds/ap/2005/11/28/ap2356920.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct